Literature DB >> 15688378

Histologic and serum risk markers for noncardia early gastric cancer.

Akiko Shiotani1, Hiroyasu Iishi, Noriya Uedo, Mitutaka Kumamoto, Yukinori Nakae, Shingo Ishiguro, Masaharu Tatsuta, David Y Graham.   

Abstract

Corpus dominant gastritis and intestinal metaplasia (IM) are considered markers of increased risk of gastric carcinoma. The aim of our study was to determine serum and histologic risk markers of gastric cancer. Antral and corpus histology, pepsinogen and gastrin 17 levels were compared among patients with history of endoscopic mucosal resection (EMR) for early gastric cancer and controls. Serum pepsinogen (PG) and gastrin 17 levels were measured by RIA. There were 53 gastric cancer patients and 75 controls. The scores for IM in each region and atrophy at the lesser curvature of the corpus were significantly higher in the cancer group than in the H. pylori-positive control group. IM at the greater curvature of the corpus and atrophy at the lesser curvature of the corpus were associated with multiple malignant lesions. Although corpus gastritis was associated with an increased risk of gastric cancer (odds ratio [OR] = 3.4; 95% confidence interval [CI] 1.6-7.0) (p = 0.001), the most important marker was the presence of IM at the lesser curvature of the corpus (OR = 15.1; 95% CI 4.3-52.6) (p < 0.001)). The best cut-off points of serum markers for gastric cancer were a PG I concentration of 45 ng/mL or less and a gastrin 17 >60 pg/mL (sensitivity = 83%; specificity = 68%). IM at the lesser curvature of the corpus and the combination of serum gastrin 17 and PG I identified a group at high risk for development of gastric cancer. Annual endoscopic follow-up is warranted for patients with IM found at the greater curvature of the corpus. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688378     DOI: 10.1002/ijc.20852

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Eradication of H. pylori did not improve abnormal sonic hedgehog expression in the high risk group for gastric cancer.

Authors:  Akiko Shiotani; Takahisa Murao; Noriya Uedo; Hiroyasu Iishi; Yoshiyuki Yamanaka; Tomoari Kamada; Hiroaki Kusunoki; Kazuhiko Inoue; Ken Haruma
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Do we need multiple biopsies for assessing gastric cancer risk?

Authors:  Noriya Uedo
Journal:  Dig Dis Sci       Date:  2011-04       Impact factor: 3.199

3.  Role of Sonic Hedgehog signaling during progression from inflammation to cancer in the stomach.

Authors:  Alexander E Sherman; Yana Zavros
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

4.  Histological risk markers for non-cardia early gastric cancer. Pattern of mucin expression and gastric cancer.

Authors:  Akiko Shiotani; Ken Haruma; Noriya Uedo; Hiroyasu Iishi; Ryu Ishihara; Masaharu Tatsuta; Mitutaka Kumamoto; Yukinori Nakae; Shingo Ishiguro; David Y Graham
Journal:  Virchows Arch       Date:  2006-10-13       Impact factor: 4.064

5.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

6.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

7.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

8.  Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.

Authors:  Sirikan Yamada; Takeshi Matsuhisa; Luksana Makonkawkeyoon; Suparp Chaidatch; Shunji Kato; Norio Matsukura
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

9.  Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.

Authors:  J-S Ren; F Kamangar; Y-L Qiao; P R Taylor; H Liang; S M Dawsey; B Liu; J-H Fan; C C Abnet
Journal:  Gut       Date:  2009-01-09       Impact factor: 23.059

10.  Serum pepsinogens and risk of esophageal squamous dysplasia.

Authors:  Farin Kamangar; Lena Diaw; Wen-Qiang Wei; Christian C Abnet; Guo-Qing Wang; Mark J Roth; Bing Liu; Ning Lu; Carol Giffen; You-Lin Qiao; Sanford M Dawsey
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.